Last updated on February 2018

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients


Brief description of study

In this observational study, blood samples for pharmacokinetic (PK) testing will be collected from subjects with metastatic prostate cancer during their treatment with docetaxel. Plasma levels of docetaxel will be determined, and the subjects docetaxel exposure levels, determined as an area under the curve (AUC), will be retrospectively correlated with reports of toxicity, tumor response, quality of life, time to disease progression and overall survival to provide guidance on what the appropriate target range for docetaxel exposure should be for metastatic prostate cancer subjects receiving docetaxel therapy for their disease.

Clinical Study Identifier: NCT02376296

Contact Investigators or Research Sites near you

Start Over

Elizabeth Goddard

UPMC CancerCenter - Washington
Washington, PA United States
  Connect »